A Study to Investigate Safety and How AZD4248 Works
Phase 1
124
about 11 months
18–75
5 sites in CA, IL, MI +2
About this study
Researchers are testing the safety, how well AZD4248 works in the body (pharmacokinetics), and how it affects the body (pharmacodynamics) when given as a pill or injection. The trial also looks at whether people with kidney disease can measure creatinine at home.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AZD4248
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part D: Intra- and inter-participant variability of estimated glomerular filtration rate (eGFR) derived from home self-testing device measurements, Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Secondary: Accumulation ratio for AUC (Rac AUC), Accumulation ratio for Cmax (Rac Cmax), Apparent total body clearance (CL/F), Dose normalized Cmax (Cmax/D), Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)], Maximum observed drug concentration (Cmax), Part D: Estimated glomerular filtration rate (eGFR), Part D: Intra- and inter-participant variability of eGFR derived from laboratory measurements
Renal